Dyadic's C1 Platform Selected by the Vaccine and Immunotherapy Center ( VIC ) at Massachusetts General Hospital as Part of VIC's $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases -October 05, 2023 at 08:32 am EDT

JUPITER, Fla., Oct. 05, 2023 -- Dyadic International, Inc. , a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein...

Related Keywords

Massachusetts ,United States ,Delaware ,Mark Emalfarb ,Mark Poznansky ,Patrickj Gallagher ,Voltron Therapeutics Inc ,Us Department Of Defense Do ,Immunotherapy Center At Massachusetts ,Securities Exchange ,Dyadic International Inc ,Immunotherapy Center ,Dyadic International ,Massachusetts General Hospital ,Voltron Therapeutics ,Self Assembling Vaccine ,Chief Executive ,Massachusetts General ,Emerging Infectious ,Lassa Fever ,Securities Act ,Securities Exchange Act ,Markets ,